fisogatinib   Click here for help

GtoPdb Ligand ID: 10220

Synonyms: BLU-554 | BLU554 | CS-3008 | CS3008
Compound class: Synthetic organic
Comment: Fisogatinib (BLU-554) is an orally bioavailable, potent and highly selective fibroblast growth factor receptor 4 (FGFR4) inhibitor. It was discovered by Blueprint Medicines [1] (probably compound number 40 therein), and is being investigated for clinical anti-tumour efficacy in cancers that are driven by FGFR4 activation (for example, in liver cancers where the FGF19/FGFR4 signalling pathway is activated by genetic alteration). Structurally, fisogatinib is a derivative of BLU-9931 and is similarly an irreversible type tryosine kinase inhibitor.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 94.6
Molecular weight 502.12
XLogP 4.3
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C=CC(=O)NC1CCOCC1Nc1ncc2c(n1)ccc(c2)c1c(Cl)c(OC)cc(c1Cl)OC
Isomeric SMILES C=CC(=O)N[C@H]1CCOC[C@H]1Nc1ncc2c(n1)ccc(c2)c1c(Cl)c(OC)cc(c1Cl)OC
InChI InChI=1S/C24H24Cl2N4O4/c1-4-20(31)28-16-7-8-34-12-17(16)30-24-27-11-14-9-13(5-6-15(14)29-24)21-22(25)18(32-2)10-19(33-3)23(21)26/h4-6,9-11,16-17H,1,7-8,12H2,2-3H3,(H,28,31)(H,27,29,30)/t16-,17+/m0/s1
InChI Key MGZKYOAQVGSSGC-DLBZAZTESA-N
No information available.
Summary of Clinical Use Click here for help
ClinicalTrials.gov has one registered BLU-554 trial (as of Feb 2019) that is a first-in-human study designed to ascertain the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of BLU- 554 as an orally delivered drug in patients with advanced FGF19-positive hepatocellular carcinoma. Click here to link to ClinicalTrials.gov's full list of BLU-554 trials. In China clinical development has been licenced to CStone Pharmaceuticals, and their research code for the compound is CS3008.
Preliminary clinical data is reported, in a review of therapies that are in development for gastrointestinal cancers, by Yee (2018) [2]. This early data shows that BLU-554 produced an anti-tumour response in patients with FGF19-positive HCC (, but not in patients with FGF19-negative HCC, a result that validates the mechanism of action of BLU-554. We await peer-reviewed publication of this data.